Jenna Payesko

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, talks about treatment options for Candida auris and multi-drug resistant treatment options.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, discusses Candida auris.

The Certified Nurse Practicioner from the Henry Ford Medical Center also weighs in the best advice to avoid cardiovascular disease.

First-in-class antibody demonstrates significant reduction in bullous pemphigoid activity.

APTIOM provides an important new treatment option for partial-onset seizures in pediatric patients ages 4 and up for adjunctive and monotherapy use.

FDA sends response letter requesting studies to assess abuse-deterrent properties of oxycodone extended release.

Alnylam Therapeutics expects to file for a New Drug Application in late 2017.

The ongoing phase 3 trial has been selected for accelerated approval pathways in the US and Europe.

AbbVie filed for elagolix approval to treat endometriosis-associated pain, and current studies are testing the same drug effectiveness for uterine fibroids.

The BARDA contract funds a specified portion of estimated costs related to the drug’s development.

Over a 12-month period, the drug showed a statistically significant reduction in the number of monthly migraine headache days.

If approved, the drug will be the first and only single-dose oral therapy available or the condition.